This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ACTG 384 was a double-blind treatment study evaluating various combinations of anti-HIV medications in people with HIV infections. The registry reports an enrollment of 900 participants and lists a broad set of antiretroviral and adjunctive interventions.
| Feature | ACTG 384 |
|---|---|
| Official title | A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection |
| Acronym | ACTG 384 |
| Condition | HIV Infections |
| Phase | NA |
| Status | Completed |
| Enrollment | 900 |
| Masking | Double |
| Primary purpose | Treatment |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| ClinicalTrials.gov | NCT00000919 |
2. Clinical Question
The registry describes ACTG 384 as a treatment study evaluating various combinations of anti-HIV medications to treat early HIV infection. The statistical question is therefore centered on comparing treatment strategies within the enrolled population while preserving the benefits of randomized clinical-trial design where applicable.
Population
People enrolled in the study with HIV infections, in the setting of treatment for early HIV infection.
Interventions
The registry lists indinavir sulfate, lamivudine/zidovudine, ritonavir, hydroxyurea, abacavir sulfate, amprenavir, nelfinavir mesylate, efavirenz, lamivudine, stavudine, zidovudine, and didanosine.
Comparator
The registry title describes evaluation of various medication combinations, but it does not provide a separately identified comparator regimen in the available record.
Primary question
How do the evaluated combinations of anti-HIV medications perform as treatment strategies for early HIV infection?
3. Trial Design
The available registry record establishes that ACTG 384 was double-blind and treatment-oriented, but it does not provide the allocation ratio, the number of randomized arms, the exact treatment assignment structure, or the sequence in which the listed medications were combined. Those design details are important because the appropriate statistical model depends on whether the study involved a simple parallel-group comparison, several treatment groups, a factorial structure, or another allocation scheme.
Intervention inventory
| Medication | Registry classification |
|---|---|
| Indinavir sulfate | Drug |
| Lamivudine/Zidovudine | Drug |
| Ritonavir | Drug |
| Hydroxyurea | Drug |
| Abacavir sulfate | Drug |
| Amprenavir | Drug |
| Nelfinavir mesylate | Drug |
| Efavirenz | Drug |
| Lamivudine | Drug |
| Stavudine | Drug |
| Zidovudine | Drug |
| Didanosine | Drug |
4. Endpoints
The ClinicalTrials.gov record does not contain registered primary endpoints for ACTG 384. Consequently, there is no registry-defined primary endpoint, endpoint definition, or endpoint time frame available to summarize here.
This distinction is especially important in a study evaluating multiple medication combinations. A valid statistical analysis needs to identify not only which treatments were compared, but also the outcome used to determine whether one strategy differed from another and the period over which that outcome was assessed.
5. Statistical Methodology
What the registry establishes
The available record identifies a double-blind treatment study with an enrollment of 900. These features have direct statistical implications. Blinding can reduce the influence of knowledge of treatment assignment on outcome assessment and participant or investigator behavior, while a randomized comparison, if used for treatment allocation, provides the basis for causal comparisons between assigned strategies.
What a complete efficacy analysis would require
A formal efficacy analysis would begin by identifying the prespecified endpoint, the treatment groups being compared, the analysis population, the timing of assessments, and the statistical hypothesis. The choice between continuous-outcome, binary-outcome, count, longitudinal, or time-to-event methods depends on the endpoint definition rather than simply on the fact that the study is a clinical trial.
Here, θ represents the relevant treatment effect for the prespecified endpoint. The exact form of θ would depend on whether the endpoint were a mean, proportion, rate, hazard, or another statistical quantity.
Analysis population
The registry record available here does not define an intention-to-treat population, per-protocol population, or safety analysis population. In a randomized trial, the intention-to-treat principle generally analyzes participants according to their assigned treatment and preserves the treatment comparison created by randomization. A safety analysis may instead be based on treatment exposure. Which populations were actually specified for ACTG 384 is not reported in the available registry information.
Multiplicity
Multiplicity becomes particularly important when a study evaluates several treatment combinations or multiple endpoints. If several hypotheses are tested, the probability of obtaining at least one apparently positive result by chance can exceed the nominal type I error rate for an individual test. Appropriate analysis therefore depends on the prespecified hierarchy, adjustment strategy, or other error-control procedure.
The registry record does not identify a multiplicity procedure for ACTG 384. No specific adjustment method should therefore be attributed to the trial from this record alone.
6. Planned Analysis
No formal statistical analyses were posted to ClinicalTrials.gov, and the record contains no registered primary endpoints. Results have not been posted on ClinicalTrials.gov.
How endpoints of different types would typically be analyzed
| Potential endpoint type | Typical statistical approach | Key interpretation issue |
|---|---|---|
| Continuous outcome | Comparison of means or an appropriate regression model | Magnitude and uncertainty of the between-group difference |
| Binary outcome | Risk difference, risk ratio, odds ratio, or regression-based comparison | Absolute and relative event probabilities should be distinguished |
| Count or rate outcome | Poisson or negative-binomial methods when appropriate | Exposure time and overdispersion may affect the analysis |
| Longitudinal outcome | Repeated-measures or mixed-effects methods when appropriate | Correlation among measurements within the same participant must be handled |
| Time-to-event outcome | Kaplan-Meier estimation, log-rank testing, and/or Cox regression when appropriate | Censoring and the proportional-hazards assumption must be considered |
These are general statistical frameworks rather than descriptions of analyses performed in ACTG 384. The appropriate method would be determined by the prespecified endpoint and analysis plan.
7. Statistical Methods Explained
Why does double-blinding matter statistically?
Blinding is a design feature intended to reduce bias arising from knowledge of treatment assignment. If participants or investigators know which treatment is being received, expectations can potentially influence behavior, reporting, treatment decisions, or outcome assessment. Double-blinding therefore strengthens the design when the outcome or conduct of treatment can be influenced by treatment knowledge.
Why is the endpoint definition more important than the statistical test?
A statistical test cannot be selected correctly until the outcome is defined. For example, a continuous measurement, a binary event, and time until an event require different estimands and often different models. The absence of registered primary endpoints means the available record does not establish which of these frameworks applies to the primary efficacy question.
Why would multiple medication combinations create a multiplicity issue?
Suppose several treatment comparisons were evaluated independently. Even if every individual null hypothesis were true, testing many hypotheses creates more opportunities for at least one small p-value to appear by chance. A prespecified multiplicity strategy can control the familywise error rate or otherwise define how the collection of hypotheses should be interpreted.
Why does randomization matter?
Randomization creates treatment groups whose assignment mechanism is independent of prognostic characteristics, in expectation. This allows differences in outcomes between randomized groups to be interpreted as treatment effects under the assumptions of the design. The available record does not provide the allocation ratio or detailed randomization scheme for ACTG 384.
Why is blinding different from randomization?
Randomization addresses how treatment groups are formed; blinding addresses knowledge of treatment assignment after allocation. They protect against different sources of bias. A trial can therefore benefit from both features, with each serving a distinct methodological purpose.
Why can't a p-value define the clinical importance of a treatment?
A p-value addresses compatibility of the observed data with a specified null hypothesis under a statistical model. It does not measure the size of a treatment effect, the probability that a treatment is beneficial, or the importance of an observed difference to patients. Effect estimates and their confidence intervals are needed to describe magnitude and precision.
8. Understanding Treatment Comparisons in a Multi-Combination Study
The phrase “various combinations” is statistically important. A study involving several medications can generate different scientific questions depending on how the combinations were constructed. Investigators might be interested in a specific regimen versus another regimen, the contribution of an individual drug, interactions among drugs, or a broader comparison of treatment strategies.
Main-effect question
A main-effect analysis asks whether inclusion of a particular treatment component is associated with a difference in the outcome, averaged over the relevant combinations.
Regimen question
A regimen comparison treats complete combinations as the treatment categories and compares outcomes between those categories.
Interaction question
An interaction asks whether the effect associated with one treatment component changes depending on another component.
Multiplicity question
Multiple comparisons require a clear definition of which hypotheses are confirmatory and how the overall error rate is controlled.
These questions are not interchangeable. A treatment-combination study can produce different conclusions depending on whether the statistical estimand concerns an individual medication, an entire regimen, or an interaction between components.
9. Confidence Intervals and Effect Estimates
When a clinical trial reports an effect estimate, a confidence interval provides information about statistical precision. The estimate describes the observed treatment contrast under the selected analysis, while the interval communicates uncertainty associated with sampling variability and the statistical model.
An effect estimate should be read together with its confidence interval rather than in isolation. The estimate is the center of the reported statistical result; the confidence interval indicates how precisely that effect was estimated under the corresponding framework.
A confidence interval is not a range containing the true effect with a fixed probability after the data have been observed. Its interpretation depends on the repeated-sampling procedure used to construct the interval.
Relative measures can be useful for comparing treatment strategies, but they do not by themselves describe the absolute frequency of an outcome. Whenever the endpoint is available, absolute event rates or differences provide an important complementary perspective.
10. Analysis of Safety
The registry information identifies the study as a treatment study and lists numerous anti-HIV medications, but it does not provide serious adverse-event counts by treatment arm or other numerical safety results.
Safety analysis is conceptually distinct from efficacy analysis. An efficacy population is typically defined around the randomized treatment comparison, whereas exposure-related safety summaries commonly consider participants who actually received study treatment. The exact safety population and adverse-event definitions for ACTG 384 are not provided in the available record.
11. Missing Data and Follow-Up
Clinical-trial analyses must account for participants who do not provide all planned outcome measurements. The statistical consequences depend heavily on the endpoint. For a single continuous endpoint, missing observations may affect the estimand and precision; for longitudinal outcomes, the timing and pattern of missing measurements can influence the analysis; for time-to-event outcomes, censoring requires an explicit definition and assumptions about the event process.
The available registry record does not specify a missing-data or imputation strategy for ACTG 384. No particular imputation method should therefore be attributed to the trial.
12. Stratification and Covariate Adjustment
Stratification can be used in randomized trials to balance important prognostic characteristics or to improve precision. Covariate adjustment can similarly account for prespecified baseline factors in an outcome model. Both approaches require clear definitions of the variables and their role in the statistical analysis plan.
The available record does not identify stratification factors or a prespecified covariate-adjustment strategy for ACTG 384. Consequently, no specific stratified analysis or adjusted regression model can be assigned to the trial from the registry information alone.
Here, T represents treatment and the X terms represent prespecified covariates. The link function g and interpretation of the coefficients depend on the endpoint type.
13. Interim Analysis and Sequential Testing
Interim analyses can allow investigators to examine accumulating evidence before the nominal end of a trial. They can be useful for monitoring efficacy, safety, or feasibility, but repeated unadjusted significance testing can increase the probability of a false-positive conclusion.
When interim efficacy testing is prespecified, group-sequential boundaries or alpha-spending methods can allocate the type I error across information times. The resulting p-values and confidence intervals must then be interpreted within that sequential design.
The available registry record does not identify an interim-analysis schedule, stopping boundary, alpha-spending approach, or information fraction for ACTG 384.
14. Bayesian Methods
Bayesian clinical-trial analysis combines prior information with the observed data to obtain a posterior distribution for the parameter of interest. A Bayesian analysis can therefore answer questions in terms of posterior probabilities or credible intervals rather than the repeated-sampling interpretation used by conventional frequentist confidence intervals.
No Bayesian analysis or prior specification is identified in the available registry information for ACTG 384. The trial should not therefore be characterized as Bayesian on the basis of the treatment-combination design alone.
15. Limitations
- No registered primary endpoints: the available ClinicalTrials.gov record contains no registered primary endpoint definitions or time frames.
- No posted statistical analyses: ClinicalTrials.gov does not provide formal statistical analyses for the study in the available record.
- No arm-level sample sizes: the record gives total enrollment of 900 but does not provide the sample size assigned to each treatment combination.
- Incomplete allocation detail: the available record does not specify the randomization ratio or detailed treatment-assignment structure.
- Combination complexity: multiple listed medications can correspond to different possible estimands, including regimen effects, component effects, and interactions.
- No numerical safety results: serious adverse-event counts by arm and other quantitative safety outcomes are not provided in the available record.
- No analysis-population definitions: the available record does not define ITT, per-protocol, or safety analysis populations.
- No missing-data strategy: the registry does not identify an imputation or missing-data analysis plan.
- No multiplicity procedure: the record does not identify how multiple treatment comparisons or endpoints were handled statistically.
- No interim-analysis details: the available information does not establish whether or how formal interim efficacy analyses were conducted.
16. Why This Trial Matters Statistically
ACTG 384 is a useful statistical teaching case because its basic design raises several central questions in clinical-trial methodology. A study evaluating multiple medication combinations requires the analyst to distinguish the treatment unit being compared from the individual drugs that make up that treatment.
| Concept | How it applies to ACTG 384 |
|---|---|
| Clinical-trial design | A treatment study enrolling 900 participants |
| Blinding | The registry identifies the study as double-blind |
| Multiple treatments | The registry lists numerous anti-HIV medications |
| Estimands | The statistical target depends on whether the analysis compares complete combinations, individual components, or interactions |
| Multiplicity | Multiple treatment combinations can create multiple statistical comparisons |
| Effect estimation | Any treatment conclusion should be expressed using an appropriate effect measure with its uncertainty |
| Analysis populations | The interpretation depends on whether analyses follow randomized assignment, treatment exposure, or another prespecified population |
| Endpoint selection | The statistical method must follow the actual prespecified outcome definition |
| Missing data | Incomplete follow-up can affect estimates and precision and requires an explicit strategy |
17. A Statistical Reading of the Study Design
The most important statistical feature visible from the registry is not a particular p-value or treatment effect. It is the relationship between treatment combinations, blinding, and the endpoint used to evaluate them.
When multiple medications are listed, the first question should be: what exactly is the randomized treatment? If the randomized unit is a complete regimen, the primary contrast is between regimens. If individual drug components are randomized independently, a factorial model may instead be appropriate. If treatment sequences or other structures are used, the model must reflect that design.
The second question is: what is the estimand? An estimand defines the treatment effect of interest in terms of the population, treatment conditions, outcome, and time frame. Without an endpoint and time frame, an effect estimate has no fully specified clinical interpretation.
The third question is: how many hypotheses are being tested? A collection of medication combinations can generate a large number of pairwise comparisons. Those comparisons need to be distinguished from a single prespecified primary comparison, because the evidentiary meaning of a nominal p-value depends on the testing strategy.
The registry establishes a substantial treatment study with 900 participants and double-blind masking, but the statistical interpretation of efficacy depends on design information that is not contained in the available endpoint and results fields. The correct analytical workflow is therefore to identify the treatment unit and prespecified endpoint first, then select the effect measure and model that match those definitions.
18. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The available record supports describing ACTG 384 as a double-blind treatment study with 900 participants and multiple listed anti-HIV medications. It does not provide registered primary endpoints or posted statistical analyses.
Clinical interpretation
The study was designed around treatment of early HIV infection using various combinations of anti-HIV medications. The clinical meaning of comparative effectiveness or safety requires the endpoint definitions and corresponding results.
This distinction prevents a common analytical error: treating the existence of a randomized or blinded trial as sufficient evidence of a particular treatment effect. Study design establishes the framework for inference; the endpoint-specific results establish the estimated effect.
19. What Can and Cannot Be Inferred From Enrollment Alone
An enrollment of 900 provides important information about the overall scale of the study, but it does not by itself determine statistical power or precision for a particular endpoint.
| Question | What enrollment can tell us | What additional information is needed |
|---|---|---|
| Study size | The registry reports 900 participants | None for the total enrollment itself |
| Precision | Larger samples generally permit more precise estimates | Event rate or outcome variability and allocation across groups |
| Statistical power | Total sample size contributes to power | Effect size, variance or event rate, alpha, allocation, and analysis method |
| Comparability | Enrollment establishes the overall study population size | Randomization and treatment-group allocation details |
| Clinical importance | Enrollment says nothing directly about the magnitude of benefit or harm | Endpoint-specific effect estimates and uncertainty |
20. A Framework for Reading Any Future Posted Result
If endpoint-specific results become available, the first step should be to identify exactly what was estimated. A statistically complete interpretation should then proceed through five questions.
This sequence keeps statistical interpretation anchored to the estimand rather than allowing a single p-value to become the entire interpretation of a clinical trial.
21. Sources
- ClinicalTrials.gov: ACTG 384 — NCT00000919.
Continue through Clinical Biostats
Explore additional clinical trial analyses, biostatistics tutorials, and statistical tools.
22. Record Summary
ACTG 384 was a completed, double-blind treatment study evaluating various combinations of anti-HIV medications in early HIV infection, with 900 participants enrolled. The registry identifies HIV infections as the condition, treatment as the primary purpose, NIAID as the lead sponsor, and NIH as the sponsor type. The listed interventions include indinavir sulfate, lamivudine/zidovudine, ritonavir, hydroxyurea, abacavir sulfate, amprenavir, nelfinavir mesylate, efavirenz, lamivudine, stavudine, zidovudine, and didanosine.
From a statistical perspective, the most important lesson is the need to connect the treatment unit, the endpoint, the estimand, and the multiplicity structure before interpreting a treatment comparison. The available ClinicalTrials.gov record establishes the study's overall design characteristics and enrollment but contains no registered primary endpoints and no posted statistical analyses. Results have not been posted on ClinicalTrials.gov.